Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
1 study found for:    NCT01322490
Show Display Options
Rank Status Study
1 Active, not recruiting A Randomized, Double-blind, Phase 3 Efficacy Trial of PROSTVAC-V/F +/- GM-CSF in Men With Asymptomatic or Minimally Symptomatic Metastatic Castrate-Resistant Prostate Cancer
Condition: Prostate Cancer Metastatic
Interventions: Biological: PROSTVAC-V;   Biological: PROSTVAC-F;   Drug: GM-CSF;   Other: GM-CSF Placebo;   Biological: Placebo

Indicates status has not been verified in more than two years